TREM1 Blockade Reprograms Tumor‐Associated Macrophages and Improves Anti‐PD‐1 Efficacy in Gastric Cancer

Abstract

The objective response rate of immune checkpoint inhibitors in patients with gastric cancer is limited. Targeting specific subtypes of macrophages holds promise for expanding the potential population sensitive to immune checkpoint inhibitors. This study aims to evaluate the key role of TREM1+tumor‐associated macrophages (TAMs) in regulating antitumor immunity.